Antibody Information
General Information of This Antibody (ID: ANTI0WFVLH)
| Antibody Name | SYD2884 |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | c-Met |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
BYON3521 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have advanced/metastatic c-MET-positive tumors (confirmed by IHC/dISH/mutation) refractory to standard therapy, ECOG ≤1, and adequate organ function. Key exclusions include prior SYD985 treatment, recent anticancer therapy (<4 weeks), active pneumonitis/cardiovascular disease, or untreated/symptomatic brain metastases. Keratitis and glomerulonephritis history also preclude participation.
Click to Show/Hide
|
||||
| Administration Dosage |
BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05323045 | Clinical Status | PHASE1 | ||
| Clinical Description |
A First-in-human Dose-escalation and Expansion Trial With the Antibody-drug Conjugate BYON3521 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With c-MET Expressing Locally Advanced or Metastatic Solid Tumours
|
||||
| Primary Endpoint |
The study evaluates safety in Part 1 (dose-escalation) by monitoring dose-limiting toxicities (DLTs) during the first 21-day cycle to determine the maximum tolerated dose (MTD).
|
||||
| Other Endpoint |
Efficacy in Part 2 (expansion cohorts) is assessed via objective response rate (ORR) at 21-day intervals across four tumor types: non-squamous NSCLC (Cohort A), gynecological cancers (B), pancreatic adenocarcinoma (C), and uveal melanoma (D), all requiring c-MET overexpression (IHC ≥2+).
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Patients with previously treated progressive locally advanced or metastatic solid tumors, MET positive.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05323045 | Clinical Status | Phase 1 | ||
| Clinical Description |
A first-in-human dose-escalation and expansion trial with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-met expressing locally advanced or metastatic solid tumours.
|
||||
References